Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group HEC.1 (CALGB 80802) - HEC.1 Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) - was closed to patient accrual on May 21, 2015.

The Alliance Data and Safety Monitoring Board (DSMB) reviewed Canadian Cancer Trials Group HEC.1 (CALGB 80802) at its meeting on May 15, 2015. The DSMB recommended that the study be closed to accrual, that the key study summary data, including that there was no improvement in overall survival and that there was an increase in the rates of grade 3 or greater adverse events, be shared with physicians. The DSMB recommended that future treatment decisions regarding whether to continue protocol therapy be left to the discretion of the physician and the patient.

Questions about this should be directed to Barbara Graham, Canadian Cancer Trials Group Study Coordinator, at or 613-533-6430.